ArticleJournal of the American Heart Association2023
Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer.
Open access · goldAbstract read
In one paragraph
Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
14.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Genome-wide analysis of heart failure yields insights into disease heterogeneity and enables prognostic prediction in the Japanese population.Nature communications · 2025Pooled it
- Cardiovascular Events Associated with CDK4/6 Inhibitors: A Safety Meta-Analysis of Randomized Controlled Trials and a Pharmacovigilance Study of the FAERS Database.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Pooled it
- QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials.JNCI cancer spectrum · 2024Pooled it
- Cardiovascular Risk Stratification and Surveillance in Cardio-Oncology: Mechanistic Foundations and Future Directions.Biomedicines · 2026Review
- Cardiovascular event burden in women with breast cancer treated with CDK4/6 inhibitors: a retrospective matched cohort study.Cardio-oncology (London, England) · 2026Article
- The double-edged sword of tumor-targeted treatment: the influence of targeted therapy on the heart.Translational cancer research · 2026Review
- Cardiovascular care in adult cancer survivorship post-therapy: a cross-sectional analysis of clinical practice guidelines.Cardio-oncology (London, England) · 2026Review
- Abemaciclib-induced myocarditis in early breast cancer: a case report.Cardio-oncology (London, England) · 2026Article
- Cardiovascular toxicity of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in HR+/HER2- breast cancer: a real-world study based on the FAERS database.Frontiers in pharmacology · 2026Article
- Integration of pre‑existing cardiovascular comorbidity into CDK4/6 inhibitor selection for breast cancer.Therapeutic advances in drug safety · 2026Article
- Cardiomyopathy temporally associated with prior palbociclib treatment successfully treated with quadruple therapy for heart failure: a case report.International cancer conference journal · 2025Article
- Exercise to Mitigate Premature Vascular Aging After Doxorubicin Breast Cancer Therapy.Exercise and sport sciences reviews · 2025Review
- Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research.JACC. CardioOncology · 2025Article
- Management of hepatotoxicity associated with CDK4/6 inhibitors and rechallenge strategies in metastatic hormone-positive, HER2-NEGATIVE BREAST CANCER.Journal of cancer research and clinical oncology · 2025Article
- CDK4/6 inhibitor in combination with aromatase inhibitor effective in metastatic hidradenocarcinoma.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.European journal of heart failure · 2025Review
- Precision Medicine for Pediatric Glioma and NF1-Associated Tumors: The Role of Small Molecule Inhibitors.Current oncology (Toronto, Ont.) · 2025Review
- Cardiovascular disease in breast cancer patients: a nationwide real-world evidence study 2013-20.European heart journal open · 2025Article
- In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy.Cancers · 2025Review
- Cyclin-dependent protein kinases and cell cycle regulation in biology and disease.Signal transduction and targeted therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 1 country.
Michael G FradleyCardio-Oncology Center of Excellence, Division of Cardiology, Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA.ORCID 0000-0001-8352-8975
Nam H K NguyenDepartment of Pharmacotherapy and Translational Research College of Pharmacy, University of Florida Gainesville FL.ORCID 0000-0003-3036-4748
David MadnickDepartment of Medicine Hospital of the University of Pennsylvania Philadelphia PA.ORCID 0000-0003-4923-4935
Yiqing ChenDepartment of Biostatistics and Data Science University of Texas Health Science Center at Houston Houston TX.ORCID 0000-0003-3282-3979
Angela DeMicheleDepartment of Medicine, Division of Hematology & Oncology Perelman School of Medicine at the University of Pennsylvania Philadelphia PA.ORCID 0000-0003-1297-4251
Igor MakhlinDepartment of Medicine, Division of Hematology & Oncology Perelman School of Medicine at the University of Pennsylvania Philadelphia PA.ORCID 0000-0001-7374-7330
Susan DentDuke Cancer Institute Duke University Durham NC.ORCID 0000-0002-9183-9340
Benedicte LefebvreCardio-Oncology Center of Excellence, Division of Cardiology, Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA.ORCID 0000-0002-8587-7279
Joseph CarverCardio-Oncology Center of Excellence, Division of Cardiology, Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA.ORCID 0000-0001-8804-0653
Jenica N UpshawCardio-Oncology Program, Division of Cardiology Tufts Medical Center Boston MA.
David DeRemerDepartment of Pharmacotherapy and Translational Research College of Pharmacy, University of Florida Gainesville FL.ORCID 0000-0002-2207-9552
Bonnie KyCardio-Oncology Center of Excellence, Division of Cardiology, Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA.ORCID 0000-0002-6628-9981
Avirup GuhaCardio-Oncology Program, Division of Cardiology, Department of Internal Medicine Medical College of Georgia at Augusta University Augusta GA.ORCID 0000-0003-0253-1174
Yan GongDepartment of Pharmacotherapy and Translational Research College of Pharmacy, University of Florida Gainesville FL.ORCID 0000-0002-8218-1620
University of Pennsylvania · USUniversity of Florida Health · USAugusta University · USDuke University · USHospital of the University of Pennsylvania · USThe University of Texas Health Science Center at Houston · USTufts Medical Center · USUniversity of Florida · US
Funding
Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2MPharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in ChildrenR01HD071779 · NICHD · UNIVERSITY OF FLORIDA · PI KWARA, AWEWURA JACOB · 2012 to 2022
$6.0MPreemptive pharmacogenetic testing in medically underserved populationsR01HG011800 · NHGRI · UNIVERSITY OF FLORIDA · PI Julio David Duarte · 2021 to 2026
$3.9MTraining Program for Applied Research and Development in Genomic MedicineT32HG008958 · NHGRI · UNIVERSITY OF FLORIDA · PI Larisa Humma Cavallari, Stephen E. Kimmel · 2018 to 2026
$3.8MPrecision antiplatelet therapy after percutaneous coronary interventionR01HL149752 · NHLBI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, LEE, CRAIG R · 2020 to 2024
$3.5MA Multi-omics evaluation of Carfilzomib-related CardiotoxicityR01HL151659 · NHLBI · UNIVERSITY OF FLORIDA · PI GONG, YAN · 2021 to 2024
$1.6MPrevention of Anthracycline Chemotherapy CardiotoxicityK08HL146959 · NHLBI · TUFTS MEDICAL CENTER · PI UPSHAW, JENICA · 2020 to 2024
$885kNCATS NIH HHS UL1 TR001427NHGRI NIH HHS R01 HG011800NHGRI NIH HHS T32 HG008958NHLBI NIH HHS K08 HL146959NHLBI NIH HHS R01 HL149752NHLBI NIH HHS R01 HL151659NICHD NIH HHS R01 HD071779
Abstract
Background Cyclin-dependent kinase (CDK) 4 and 6 inhibitors have significantly improved survival in patients with hormone receptor-positive metastatic breast cancer. There are few data regarding the epidemiology of cardiovascular adverse events (CVAEs) with these therapies. Methods and Results Using the OneFlorida Data Trust, adult patients without prior cardiovascular disease who received at least 1 CDK4/6 inhibitor were included in the analysis. CVAEs identified from
Indexed as
Atrial FibrillationBreast NeoplasmsCardiovascular SystemHeart FailureAdultCyclin-Dependent Kinase 4FemaleHumansCyclin-Dependent Kinase 4breast cancercardio‐oncologycardiotoxicityCDK4/6 inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.